Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of ...

Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early ...

1. Consider bronchiectasis in persistent productive cough. Think of bronchiectasis in patients who have a persistent productive cough for many years with increased sputum production or recurrent chest ...

08:20, Tue, Aug 22, 2017 Updated: 08:22, Tue, Aug 22, 2017 Bronchiectasis is a long-term condition affecting over 200,000 people in the UK. The numbers are rising – over the past ten years the number ...

BRIDGEWATER, N.J. - Insmed (NASDAQ:INSM) Incorporated (NASDAQ:INSM), a biopharmaceutical company, reported positive results today from its Phase 3 ASPEN study of brensocatib for treating non-cystic ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

The "Bronchiectasis: Opportunity Assessment and Forecast Update" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive overview of bronchiectasis, highlighting ...